share_log

Immuneering | 8-K: Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic

Immuneering | 8-K: Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic

Immuneering | 8-K:Immuneering公佈2024年第三季度財務業績並提供最新業務——公佈了積極的初步數據,包括完全和部分反應,IMM-1-104與一線胰腺癌患者聯合化療-
美股SEC公告 ·  11/14 05:08
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息